Effects of different hormone replacement regimens on postmenopausal women with abnormal lipid levels

Climacteric

Volumn 1, Issue 1, 1998, Pages 26-32

  Pickar, J H ^a   Wild, R A ^b   Walsh, B ^c   Hirvonen, E ^d   Lobo, R A ^e  

^a WYETH AYERST RESEARCH   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Conjugated estrogens; High density lipoprotein; Hormone replacement therapy; Lipids; Low density lipoprotein; Medroxyprogesterone acetate; Premarin

Indexed keywords

CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO; TRIACYLGLYCEROL;

ARTICLE; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; METHODOLOGY; POSTMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, HDL2; MEDROXYPROGESTERONE 17-ACETATE; PLACEBOS; POSTMENOPAUSE; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 0032028505     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697139809080678     Document Type: Article

References (25)

1. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71
2. Speroff L. Menopause and hormone replacement therapy. Clin Geriatr Med 1993;9:33-55
3. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-61
4. 3 and calcium. Clin Endocrinol 1982;16:515-24
5. Consensus Conference, Osteoporosis. NIH Consensus Development Panel Statement. J Am Med Assoc 1984;252:799-802
6. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med 1991; 90:107-10
7. Falkeborn M, Persson I, Adami H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8
8. Lobo RA. Estrogen and cardiovascular disease. Ann NY Acad Sci 1990;592:286-94
9. Sullivan JM, Van der Swaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Arch Intern Med 1990;150:2557-62
10. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in post-menopausal women. Arch Intern Med 1991;154: 1333-9
11. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489-94
12. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9
13. Stampfer MJ, Colditz GA, Willett WC, et al. Post-menopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurse's Health Study. N Engl. J Med 1991;325:756-62
14. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1080-6
15. Henderson BE, Ross RK, Paganini-Hill A, et al. Estrogen use and cardiovascular disease. Am J Obstet Gynecol 1986;154:1181-6
16. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988;159:312-17
17. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8
18. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. J Am Med Assoc 1991;265:1861-7
19. Tikkanen MJ. Mechanisms of cardiovascular protection by post-menopausal hormone replacement therapy. Cardiovasc Risk Factors 1993;3: 138-43
20. Riedel M, Rafflenbeul W, Lichtlen P. Ovarian sex steroids and atherosclerosis. Clin Invest 1993;71: 406-12
21. Bush TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In Korenman SG, ed. The Menopause. Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Norwell, MA: Serono Symposium, 1990:211-23
22. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E for the Menopause Study Group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994;84:987-95
23. The Postmenopausal Estrogen/Progestins Interventions (PEPI) Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199-208
24. Berry DA, Eaton ML, Ekhom BP, Fox TL. Assessing differential drug effect. Biometrics 1984;40: 1109-15
25. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220-5